InMed Pharmaceuticals Inc (NASDAQ: INM)’s stock price has increased by 78.92 compared to its previous closing price of 2.49. However, the company has seen a 61.41% increase in its stock price over the last five trading sessions. newsfilecorp.com reported 2025-05-12 that Vancouver, British Columbia–(Newsfile Corp. – May 12, 2025) – InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2025 which ended March 31, 2025. The Company’s full financial statements and related MD&A for the third quarter ended March 31, 2025, are available at www.inmedpharma.com, www.sedarplus.com and at www.sec.gov.
Is It Worth Investing in InMed Pharmaceuticals Inc (NASDAQ: INM) Right Now?
Additionally, the 36-month beta value for INM is 0.27. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for INM is 0.17M and currently, short sellers hold a 54.06% ratio of that float. The average trading volume of INM on June 02, 2025 was 93.98K shares.
INM’s Market Performance
INM stock saw an increase of 61.41% in the past week, with a monthly gain of 44.17% and a quarterly increase of 56.32%. The volatility ratio for the week is 4.38%, and the volatility levels for the last 30 days are 9.49% for InMed Pharmaceuticals Inc (INM). The simple moving average for the last 20 days is 58.29% for INM stock, with a simple moving average of 9.57% for the last 200 days.
INM Trading at 65.09% from the 50-Day Moving Average
After a stumble in the market that brought INM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.62% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INM starting from MANCINI ALEXANDRA DIANE JANET, who sale 240 shares at the price of $0.18 back on Jul 31 ’24. After this action, MANCINI ALEXANDRA DIANE JANET now owns 0 shares of InMed Pharmaceuticals Inc, valued at $42 using the latest closing price.
Stock Fundamentals for INM
Current profitability levels for the company are sitting at:
- -1.77 for the present operating margin
- -2.67 for the gross margin
The net margin for InMed Pharmaceuticals Inc stands at -2.68. The total capital return value is set at -0.57. Equity return is now at value -91.71, with -73.43 for asset returns.
Based on InMed Pharmaceuticals Inc (INM), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -18.63.
Currently, EBITDA for the company is -7.06 million with net debt to EBITDA at 1.04. When we switch over and look at the enterprise to sales, we see a ratio of -1.79. The receivables turnover for the company is 6.46for trailing twelve months and the total asset turnover is 0.26. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.49.
Conclusion
In conclusion, InMed Pharmaceuticals Inc (INM) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high..
